ROCKVILLE, Md., March 12, 2024 /PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction.

马里兰州罗克维尔，2024年3月12日/PRNewswire/--专家系统公司是人工智能药物发现领域的领导者，它宣布扩大与艾琳治疗公司的合作，因为它加入了新的PTPN2抑制剂计划，艾琳最近在全股权交易中从Ness治疗公司（Ness）收购了该计划。

'Eilean's lead PTPN2 inhibitor molecules demonstrate exceptional efficacy, selectivity, oral bioavailability and a good safety profile,' commended Bill Farley, CBO at Expert Systems. 'We're proud to be Eilean's partner & leverage our cutting-edge AI platform to help advance a new pipeline of best-in-class immuno-oncological therapy solutions with an improved safety and tolerability profile.'

专家系统CBO比尔·法利（BillFarley）称赞道：“艾琳（Eilean）的主要PTPN2抑制剂分子表现出优异的疗效、选择性、口服生物利用度和良好的安全性。”我们很自豪能成为艾琳的合作伙伴，利用我们最前沿的人工智能平台，帮助推进一条新的同类最佳免疫肿瘤治疗解决方案管道，提高安全性和耐受性。”

About Eilean Therapeutics' PTPN2 Inhibitor Program

关于Eilean Therapeutics的PTPN2抑制剂计划

Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is ubiquitously expressed, primarily in hematopoietic and placental cells. As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ.

蛋白酪氨酸磷酸酶非受体2型（PTPN2），也称为T细胞蛋白酪氨酸磷酸酶（TC-PTP），主要在造血细胞和胎盘细胞中普遍表达。作为JAK-STAT途径的关键负调节剂，PTPN2的功能是通过细胞因子受体（包括IFNγ）直接调节信号传导。

Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.

因此，通过抑制PTPN2来增强IFNγ的感应和信号传导是提高癌症免疫治疗方案疗效的潜在治疗策略。

About Expert Systems, Inc.

关于专家系统公司

Expert Systems, Inc., an advanced accelerator platform, is equipped with a comprehensive, hybrid AI-based system that covers the entire spectrum of preclinical drug discovery and early development phases. This includes target identification, virtual screening, non-clinical and clinical pharmacology, chemical liability assessment, and toxicology.

专家系统公司是一个先进的加速器平台，配备了一个全面的、基于人工智能的混合系统，涵盖了临床前药物发现和早期开发阶段的整个范围。这包括目标识别，虚拟筛选，非临床和临床药理学，化学责任评估和毒理学。

Utilizing a unique combination of proprietary and public databases, Expert Systems employs specialized software tools to evaluate the intellectual property landscape and construct a competitive drug intelligence strategy to de-risk candidate selection for rapid transition from in silico to first-in-human trials.

专家系统利用专有数据库和公共数据库的独特组合，使用专门的软件工具来评估知识产权状况，并构建竞争性药物情报战略，以降低候选人选择的风险，从而从计算机快速过渡到首次人体试验。

Expert Systems has been pivotal in establishing seed and Series A companies, organizing and managing over 30 research and development programs across various financial investors and strategic partners in North America, Europe, and Australia.

专家系统在建立种子公司和A系列公司、组织和管理北美、欧洲和澳大利亚各种金融投资者和战略合作伙伴的30多个研发项目方面发挥了关键作用。

About Eilean Therapeutics

关于Eilean Therapeutics

Eilean Therapeutics LLC is a cutting-edge biopharmaceutical company, established through a collaboration between Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, dedicated to the identification of both best-in-class and first-in-class small molecule inhibitors targeting escape mutations in both hematologic and solid cancers.

Eilean Therapeutics LLC是一家尖端生物制药公司，由Orbimed，Torrey Pines Investment和John C.Byrd博士合作成立，致力于鉴定针对血液和实体癌逃逸突变的一流和一流小分子抑制剂。

The company harnesses the Expert Systems Inc. hybrid AI platform alongside its key partners' exclusive data, chem-bio platforms, knowledge, and expertise. This enables Eilean Therapeutics to select molecular mechanisms of pathology with high clinical relevance, precisely designing and expediting the discovery and development processes for leading-edge therapies.

该公司利用Expert Systems Inc.混合人工智能平台及其关键合作伙伴的独家数据、化学生物平台、知识和专业知识。这使Eilean Therapeutics能够选择具有高度临床相关性的病理学分子机制，精确设计并加速前沿疗法的发现和开发过程。

Eilean Therapeutics is committed to leveraging its unique capabilities and platform to create novel, groundbreaking medicines for patients with hematologic and solid malignancies, marking a new era in targeted cancer therapy.

Eilean Therapeutics致力于利用其独特的功能和平台，为血液和实体恶性肿瘤患者创造新颖的开创性药物，标志着靶向癌症治疗的新时代。